Key result
Aspirin's reported protection against first non-fatal myocardial infarction may be confounded by unmeasured over-the-counter use and socioeconomic factors, as aspirin users had 30% more smokers.
Why the study?
Does aspirin or non-aspirin NSAIDs prevent first non-fatal myocardial infarction in post-menopausal women?
Does aspirin or non-aspirin NSAIDs prevent first non-fatal myocardial infarction in post-menopausal women?
Answers are grounded in this paper and cite their sources.
This commentary highlights the limitations of using prescription databases for studying aspirin in primary prevention due to unmeasured over-the-counter use and socioeconomic confounding.
Garcia Rodriguez et al have conducted a cohort study to investigate differential effects of aspirin and non-aspirin NSAIDs in the primary prevention of myocardial infarction in post-menopausal women. 1 They reported that aspirin, but not non-aspirin NSAIDs, offers protection against development of first non-fatal myocardial infarction in women. We have some reservations regarding the validity of their data. Information about drug use was obtained from the UK General Practice Research Database. Approximately 3 million residents in England and Wales are registered with general practitioners who participate in this scheme, which is a computerised system of recording clinical diagnoses and prescribed drugs. The database does not contain information regarding over-the-counter medication or compliance with prescribed drugs. We question their assumption that United Kingdom patients would not take prophylactic aspirin without a prescription from their general practitioner. Additionally, the authors did not consider the possible effects of socio-economic status differences in the study population. The prevalence of Coronary Heart Disease (CHD) is much higher in lower socio-economic classes. 2 Higher socio-economic classes are generally more aware of risk factors for CHD and perhaps more likely to request prophylactic medication. Furthermore, there are differences in price between aspirin and non-aspirin NSAIDs, which may lead to variations in self-medication practice. Aspirin is significantly cheaper over the counter than on prescription, but the difference is not so marked for non-aspirin NSAIDs. There is also likely to be a difference in lifestyle factors. The only indication that the authors may have addressed this issue is their finding that there were 30% more smokers among women taking aspirin. It is generally accepted that smoking is more prevalent among those of lower socio-economic class. 3 Although the GP Research Database is a valuable and easily accessible source of information, we suggest that further studies should incorporate data on over-the-counter sales.
No takes yet. Share an insight, caveat, or question.
Hyams et al. (2001) conducted a letter in Myocardial infarction. Aspirin and non-aspirin NSAIDs was evaluated on First non-fatal myocardial infarction. Aspirin's reported protection against first non-fatal myocardial infarction may be confounded by unmeasured over-the-counter use and socioeconomic factors, as aspirin users had 30% more smokers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: